Key Takeaways:
The FDA granted Priority Review to Roche's Tecentriq plus chemotherapy for stage III dMMR colon cancer after a study showed a 50% lower recurrence risk.
"This filing acceptance brings us closer to establishing adjuvant Tecentriq plus chemotherapy as a new standard of care for certain types of early colon cancer," Levi Garraway, MD, PhD, Roche's chief medical officer and head of global product development, said.
The phase III ATOMIC study, published in the New England Journal of Medicine, enrolled 712 patients across multiple centers. At 36 months, disease-free survival reached 86% for those receiving Tecentriq plus FOLFOX6 chemotherapy, compared with 76% for chemotherapy alone — an absolute improvement of 10 percentage points. The safety profile was consistent with prior studies of both drugs, Roche said.
Nearly one in three patients with stage III colon cancer relapse within five years, according to research published in JAMA Oncology and Annals of Oncology. About 15% of colon cancer patients have dMMR/MSI-H tumors, which carry high mutation rates and respond well to immunotherapy. If approved by the Oct. 9 deadline, Tecentriq plus chemotherapy would become the first immunotherapy-based adjuvant option for this population.
Colon cancer remains one of the world's most common and deadliest tumors, with more than 1 million people diagnosed globally each year, per the World Health Organization. Despite surgery and standard chemotherapy, about 30% of stage III patients relapse within five years. dMMR, or deficient DNA mismatch repair, is a biomarker indicating a tumor's inability to correct DNA replication errors, making it more visible to the immune system and a strong target for PD-L1 inhibitors like Tecentriq.
Roche is pursuing additional regulatory filings, including with the European Medicines Agency, to bring the combination to patients worldwide. The ATOMIC study was sponsored by the National Cancer Institute and conducted by the Alliance for Clinical Trials in Oncology in partnership with Roche and the Arbeitsgemeinschaft Internistische Onkologie group in Germany. Tecentriq is the first PD-(L)1 cancer immunotherapy available in both intravenous and subcutaneous formulations.
"One in three patients with stage III colon cancer will relapse within five years, underscoring the need for new adjuvant treatment options," Michael Sapienza, CEO of the Colorectal Cancer Alliance, said. "This milestone represents a critical step toward a reality where treatment is tailored to a patient's specific tumor biology from the very beginning."
The Priority Review designation shortens the FDA's review to six months from the standard 10 months, reflecting the agency's view that the therapy could offer a significant improvement over existing options. Investors will watch for the Oct. 9 decision, which could open a new market for Tecentriq in early-stage disease and strengthen Roche's oncology portfolio against competitors including Merck's Keytruda and Bristol-Myers Squibb's Opdivo in the immuno-oncology space.
This article is for informational purposes only and does not constitute investment advice.
